Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.
Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.